Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Roberto Leon Ferre (NPI 1427361377)

Field	Value
Entity Type	Individual
Organization	Roberto Leon Ferre
Address	200 1st St Sw
City	Rochester
State	MN
ZIP	55905
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 21, 2010

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

ROBERTO LEON FERRE is enumerated as a Medical Oncology Physician (NPI enumerated: 2010-07-21 (~16 years ago)) practicing in ROCHESTER, MN and has reported Total Medicare revenue: $1.3M with no Medicaid billing on file. This makes the provider effectively single‑payer in the available data set, with Medicare representing the entirety of recorded public-payor revenue.

Revenue concentration is high: the precomputed top 3 Medicare codes by revenue account for 81.9% of this provider's total Medicare revenue. That concentration is driven primarily by J9271 (52.1% of Medicare revenue) and J9144 (22.0% of Medicare revenue), with J9299 contributing 7.8%.

The code mix indicates an outpatient oncology infusion operation focused on high-cost monoclonal antibodies and immune checkpoint inhibitors. The top codes are J9271 (pembrolizumab), J9144 (daratumumab + hyaluronidase), and J9299 (nivolumab), and the presence of chemotherapy administration codes such as 96413 (318 claims, $33.1K revenue) and infusion add‑ons (96417, 96415) supports a workflow centered on in‑clinic drug infusions and associated infusion services.

J9271 shows meaningful scale for this provider: 17K claims and $697K revenue, and it ranks #553 of 1841 providers nationally (69th percentile; typical, unremarkable volume). This percentile position suggests the provider bills pembrolizumab at an above‑median but not market‑leading level relative to national peers.

J9144 activity (7.7K claims, $294.5K revenue) ranks #319 of 615 providers nationally (48th percentile; typical, unremarkable volume), indicating participation near the middle of the national distribution for daratumumab billing. By contrast, J9299 (4.3K claims, $103.7K revenue) ranks #496 of 505 providers nationally (2th percentile; typical, unremarkable volume), signaling a minimal national presence for nivolumab relative to peers who bill that code.

Per‑claim payment levels on the top three drugs are relatively modest in isolation—$41 avg paid/claim for J9271, $38 avg paid/claim for J9144, and $24 avg paid/claim for J9299—yet large claim counts concentrate revenue. The combination of high claim volumes for these drug codes and lower per‑claim averages explains how a small set of drug administrations can produce most of the $1.3M Medicare revenue.

Operationally, the provider pairs infusion drug billing with evaluation and management and specialized infusion services, which is visible in non‑drug codes: 99214 (77 claims, $7.1K revenue), G0498 (36 claims, $7.6K revenue), and multiple chemotherapy administration/add‑on codes (96413, 96417, 96415). This mix is consistent with a clinic that delivers both clinician face‑to‑face management and the technical infusion services required for oncology biologics.

The absence of any Medicaid billing on file highlights payer concentration risk and a Medicare-dependent revenue profile. Combined with long tenure (NPI enumerated: 2010-07-21 (~16 years ago)), the provider appears established in the Medicare oncology market but would show limited visibility or scale in Medicaid-managed markets based on the available data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

46 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,000	$40	$697K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	7,750	$40	$294.5K
J9299	Injection, nivolumab, 1 mg	4,320	$20	$103.7K
J9034	Injection, bendamustine hcl (bendeka), 1 mg	3,070	$10	$39.9K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,590	$20	$35K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	320	$100	$33.1K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	2,450	$10	$24.4K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	160	$130	$20.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	910	$20	$20K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	160	$80	$12.3K

Showing 1–10 of 46

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 46 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Roberto Leon Ferre — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

46 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	70	7,200	$40	$323.3K
J9144	3	50	3,780	$40	$163.7K
J9299	17	20	5,240	$20	$159.4K
J2506	15	20	290	$80	$34.3K
Q5118	11	20	990	$20	$33.7K
J9034	1	10	2,340	$10	$30.1K
Q5119	8	30	1,380	$20	$29.5K
J9264	7	10	2,760	$10	$27.1K
J9217	19	80	80	$130	$17.1K
96413	16	230	70	$100	$11.5K

Showing 1–10 of 46

Nearby Providers

Other providers in the same ZIP code as Roberto Leon Ferre, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$74.3M
Mayo Collaborative Services, Inc	MN	Clinical Medical Laboratory	$6.5M	$39.2M
Mayo Clinic	MN	Clinical Medical Laboratory	$12.2M	$15.2M
Mayo Clinic	MN	Multi-Specialty Clinic/Center	$0	$10.9M
Mayo Foundation For Medical Education & Research	MN	Durable Medical Equipment & Medical Supplies	$9.3K	$2.8M
Vidhu Kaushik	MN	Clinical Pathology/Laboratory Medicine Physician	$59.6K	$1.9M
Peter Noseworthy	MN	Cardiovascular Disease Physician	$1.1M	$0
Daniel Childs	MN	Medical Oncology Physician	$1.1M	$0
Robert Jacobson	MN	Pediatrics Physician	$975.6K	$0
Brittany Siontis	MN	Medical Oncology Physician	$960.6K	$0

Roberto Leon Ferre — Billing Profile & Reimbursement Data

Sign up for Roberto Leon Ferre — Billing Profile & Reimbursement Data policy alerts

Roberto Leon Ferre — Billing Profile & Reimbursement Data

Sign up for Roberto Leon Ferre — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Nearby Providers

Frequently Asked Questions

References